{
  "id": "antagonist",
  "title": "Antagonist",
  "lang": "en",
  "source_lang": "en",
  "summary": "An antagonist is a substance that blocks or reduces the action of an agonist, usually by binding to a receptor without activating it.",
  "category": "health",
  "subcategory": "drugs",
  "type": "concept",
  "aliases": [
    "Receptor antagonist",
    "Pharmacological antagonist"
  ],
  "generated_at": "2026-11-04",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/antagonist/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/antagonist/",
      "json": "https://aiwiki.page/zh/antagonist.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "An antagonist is a substance that blocks or reduces the action of an agonist, usually by binding to a receptor without producing the activation caused by that agonist. In pharmacology, receptor antagonists are distinguished from substances that reduce biological activity through other mechanisms, such as inhibiting an enzyme or preventing the production of a signaling molecule. In a broader sense, antagonism also describes interactions in which one substance opposes another’s physiological effects without necessarily acting at the same receptor."
    },
    {
      "heading": "Receptor binding and activity",
      "text": "Receptors are proteins that recognize signaling molecules and influence cellular activity. Their natural activators include neurotransmitters and hormones. An antagonist can occupy a receptor, or alter its ability to respond, and thereby interfere with signaling.\n\nTwo properties are central to understanding receptor antagonism:\n\n- Affinity describes how strongly a substance binds to a receptor.\n- Efficacy describes its capacity to produce a receptor-mediated response after binding.\n\nA conventional, neutral antagonist has affinity but no efficacy for activating the receptor in the response being measured. Binding alone therefore does not establish whether a substance is an agonist or an antagonist. Its functional effects must also be measured.\n\nAntagonist activity depends on the experimental or physiological context. Relevant factors include the concentration of the agonist, receptor abundance, signaling pathways, and the time available for binding and dissociation. These relationships form part of pharmacodynamics."
    },
    {
      "heading": "Major types of receptor antagonism",
      "text": "Reversible competitive antagonism\n\nA reversible competitive antagonist competes with an agonist for the same binding site, commonly the orthosteric site recognized by the receptor’s natural signaling molecule. Because binding is reversible, increasing the agonist concentration can overcome the blockade under equilibrium conditions.\n\nIn an ideal experimental system, a competitive antagonist shifts the agonist’s concentration–response curve to the right without reducing the maximum response. More agonist is required to produce a given effect, but the same maximum remains attainable.\n\nFor simple equilibrium competition, the dose ratio is:\n\n\\[DR = 1 + \\frac{[B]}{K_B}\\]\n\nHere, \\(DR\\) is the ratio of agonist concentrations required to produce the same response with and without antagonist, \\([B]\\) is the free antagonist concentration, and \\(K_B\\) is its equilibrium dissociation constant. This relationship underlies Schild analysis, a method used to characterize competitive antagonism. It assumes conditions such as equilibrium and simple competition; clinical responses need not follow it precisely.\n\nIrreversible antagonism\n\nAn irreversible antagonist binds in a way that does not readily reverse, often through a covalent interaction. Increasing agonist concentration cannot displace an antagonist that has irreversibly occupied the receptor.\n\nIrreversible blockade can reduce the maximum response. However, tissues may contain spare receptors: enough receptors to generate a maximal response without activating the entire receptor population. In such tissues, some irreversible blockade may occur before the maximum response declines.\n\nThe duration of irreversible antagonism can depend on receptor replacement rather than simply on elimination of the antagonist from the bloodstream.\n\nNoncompetitive and allosteric antagonism\n\nNoncompetitive antagonism describes blockade that cannot be fully overcome by increasing agonist concentration under the conditions being studied. It commonly reduces the maximum response, although the observed pattern depends on receptor reserve and the experimental system. It is a functional description rather than one unique molecular mechanism.\n\nAn allosteric antagonist binds at a site distinct from the agonist’s binding site and reduces agonist binding, receptor activation, or both. Such substances are often described as negative allosteric modulators. Their effects can vary with the agonist and signaling pathway examined.\n\nThese categories are not interchangeable. Irreversible binding and allosteric modulation can both produce insurmountable antagonism, but they do so through different mechanisms. Very slow dissociation can also make a reversible antagonist appear insurmountable during a short experiment."
    },
    {
      "heading": "Distinction from related drug actions",
      "text": "Inverse agonists\n\nSome receptors exhibit constitutive activity, meaning that they signal even when no agonist is bound. A neutral antagonist blocks agonist action without changing this baseline activity. An inverse agonist instead reduces constitutive activity by favoring less active receptor states.\n\nMany medicines traditionally called antagonists are more precisely classified as inverse agonists in suitable experimental systems. Many H1 antihistamines, including cetirizine and loratadine, have inverse agonist activity. The traditional clinical terminology nevertheless remains widely used.\n\nPartial agonists\n\nA partial agonist activates a receptor but produces a lower maximum response than a full agonist in the same system. When both compete for the same receptor population, the partial agonist can reduce the full agonist’s effect by occupying receptors while activating them less strongly.\n\nThus, a substance can produce agonist effects when given alone and antagonist-like effects in the presence of a more efficacious agonist.\n\nPhysiological and chemical antagonism\n\nPhysiological, or functional, antagonism occurs when substances act through different mechanisms to produce opposing effects. For example, a substance that contracts airway smooth muscle and another that relaxes it may oppose each other without competing at one receptor.\n\nChemical antagonism occurs through direct chemical interaction, such as binding or neutralization, rather than receptor competition. This differs from receptor antagonism even when the resulting reduction in biological effect appears similar."
    },
    {
      "heading": "Medical applications",
      "text": "Receptor antagonists are used across many areas of medicine. Examples include:\n\nClass or example | Principal target | Established application\nNaloxone | [[opioid | Opioid]] receptors, particularly μ receptors\n[[losartan | Losartan]] | Angiotensin II AT1 receptors\nMuscarinic antagonists, such as atropine | Muscarinic acetylcholine receptors | Applications including treatment of certain symptomatic bradycardias\nH2 receptor antagonists | Histamine H2 receptors | Reduction of gastric acid secretion\nMany antipsychotic medicines | [[dopamine | Dopamine]] D2 receptors, among other targets\n\nThese examples do not imply that each medicine acts exclusively at one receptor or that receptor blockade accounts for every clinical effect. Some medicines have several targets, and receptor subtype selectivity is often relative rather than absolute."
    },
    {
      "heading": "Interpretation and limitations",
      "text": "Antagonist potency is not a fixed measure of clinical effectiveness. The concentration needed to suppress a response depends on agonist concentration, receptor affinity, tissue exposure, and the biological system used for measurement. An inhibitory concentration measured in one assay therefore cannot automatically be treated as a universal binding constant.\n\nPharmacokinetics also affects the onset and duration of blockade. Distribution into tissues, metabolism, elimination, and receptor residence time can produce differences between blood concentration and observed effect.\n\nAntagonists may block normal signaling as well as unwanted signaling. Adverse effects can result from the intended receptor blockade or from activity at additional targets. Sustained blockade may also induce compensatory changes, including altered receptor abundance or sensitivity. Consequently, identifying a substance as an antagonist describes an important mechanism of action, but does not by itself establish its clinical benefit, safety, or appropriate use."
    }
  ],
  "links": [
    "pharmacology",
    "enzyme",
    "hormone",
    "pharmacodynamics",
    "dose-response-relationship",
    "antihistamine",
    "cetirizine",
    "loratadine",
    "opioid",
    "losartan",
    "hypertension",
    "dopamine",
    "schizophrenia",
    "pharmacokinetics"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}